Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics.
Robert RitzelSujoy GhoshRifat EmralRachid MalekLongyi ZengMaria Aileen MabunayWolfgang LandgrafPatricia GuyotPaul SerafiniDivya PushkarnaRayaz Ahmed MalikPublished in: Diabetes, obesity & metabolism (2023)
In insulin-naïve patients with T2D inadequately controlled on OADs, commencing Gla-300 shows a comparable HbA1c reduction, but with significantly less weight gain and a lower incidence of any and confirmed hypoglycaemia compared with commencing IDegAsp.